Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Neural network analysis as a novel skin outcome in a trial of belumosudil in patients with systemic sclerosis.
Gunes I, Bernstein EJ, Cowper SE, Panse G, Pradhan N, Camacho LD, Page N, Bundschuh E, Williams A, Carns M, Aren K, Fantus S, Volkmann ER, Bukiri H, Correia C, Kolachalama VB, Wilson FP, Mawe S, Mahoney JM, Hinchcliff M. Gunes I, et al. Among authors: bukiri h. Arthritis Res Ther. 2025 Apr 11;27(1):85. doi: 10.1186/s13075-025-03508-9. Arthritis Res Ther. 2025. PMID: 40217251 Free PMC article.
Neural network analysis as a novel skin outcome in a trial of belumosudil in patients with systemic sclerosis.
Gunes I, Bernstein E, Cowper SE, Panse G, Pradhan N, Camacho LD, Page N, Bundschuh E, Williams A, Carns M, Aren K, Fantus S, Volkmann ER, Bukiri H, Correia C, Wang R, Kolachalama V, Wilson FP, Mawe S, Mahoney JM, Hinchcliff M. Gunes I, et al. Among authors: bukiri h. Res Sq [Preprint]. 2024 Oct 15:rs.3.rs-4889334. doi: 10.21203/rs.3.rs-4889334/v1. Res Sq. 2024. Update in: Arthritis Res Ther. 2025 Apr 11;27(1):85. doi: 10.1186/s13075-025-03508-9. PMID: 39483897 Free PMC article. Updated. Preprint.
Clinical Characteristics of Anti-Synthetase Syndrome: Analysis From the Classification Criteria for Anti-Synthetase Syndrome Project.
Faghihi-Kashani S, Yoshida A, Bozan F, Zanframundo G, Rozza D, Loganathan A, Dourado E, Sambataro G, Bauer-Ventura I, Bae SS, Lim D, Rivero-Gallegos D, Yamano Y, Selva-O'Callaghan A, Mammen AL, Scirè CA, Montecucco C, Oddis CV, Fiorentino D, Bonella F, Miller FW, Lundberg IE, Schmidt J, Rojas-Serrano J, Hudson M, Kuwana M, González-Gay MA, McHugh N, Corte TJ, Doyle TJ, Werth VP, Gupta L, Perez Roman DI, Bianchessi LM, Devarasetti PK, Shinjo SK, Luppi F, Cavazzana I, Moghadam-Kia S, Fornaro M, Volkmann ER, Piga M, Loarce-Martos J, De Luca G, Knitza J, Wolff-Cecchi V, Sebastiani M, Schiffenbauer A, Rider LG, Campanilho-Marques R, Marts L, Bravi E, Gunawardena H, Aggarwal R, Cavagna L; Classification Criteria for Anti‐Synthetase Syndrome Project participating investigators. Faghihi-Kashani S, et al. Arthritis Rheumatol. 2025 Apr;77(4):477-489. doi: 10.1002/art.43038. Epub 2024 Dec 17. Arthritis Rheumatol. 2025. PMID: 39467037 Free PMC article.
Current advances in the treatment of systemic sclerosis.
Bukiri H, Volkmann ER. Bukiri H, et al. Curr Opin Pharmacol. 2022 Jun;64:102211. doi: 10.1016/j.coph.2022.102211. Epub 2022 Apr 18. Curr Opin Pharmacol. 2022. PMID: 35447517 Free PMC article. Review.